Avril Dieser
Vermogen: 10 700 $ op 31-05-2026
Vermogen: 10 700 $ op 31-05-2026
Avril McKean Dieser is an Independent Non-Executive Director at OS Therapies, Inc. since 2024.
Ms. Dieser is Vice President & Head-Legal Patient Evidence at UCB, Inc. since 2016.
Ms. Dieser was a Member at AbbVie, Inc. from 2013 to 2016.
Ms. Dieser completed graduate degrees at the University of Maryland and Columbus School of Law, and an undergraduate degree at Duquesne University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 22-01-2026 | 5.000 ( 0,01% ) | 10 700 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| OS THERAPIES INCORPORATED | Directeur/Bestuurslid | 28-10-2024 |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Corporate Officer/Principal | 01-08-2016 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01-07-2016 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OS Therapies, Inc.
OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau